Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02364596 · ClinicalTrials.gov registry record · Phase 1
Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
A Phase 1 study of Staphylococcal Infections, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT02364596 is a Phase 1 study of Staphylococcal Infections that has completed, run by Pfizer. The registered enrollment target is 100 participants, below the 263-participant average among 3 other Staphylococcal Infections trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02364596, a Phase 1 study of Staphylococcal Infections, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of a single vaccination of an investigational vaccine against Staphylococcus aureus (SA4Ag) in healthy adults aged 18 to \<65 years.
Conditions Studied
Interventions
- BIOLOGICAL SA4Ag vaccine
- PROCEDURE Blood sample
Study Locations (2)
Florida
- Broward Research Group - Hollywood
- Miami Research Associates - South Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02364596
The ClinicalTrials.gov registry entry for NCT02364596 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 263-participant average among 3 other Staphylococcal Infections trials with a reported enrollment target (62% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Staphylococcal Infections appearing as the primary indexed condition, and to 2 interventions - of which SA4Ag vaccine is the first listed.
NCT02364596 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02364596 about?
NCT02364596 is a clinical study titled "Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years". The purpose of this study is to evaluate the safety and immunogenicity of a single vaccination of an investigational vaccine against Staphylococcus aureus (SA4Ag) in healthy adults aged 18 to \<65 years.
What is the current status of trial NCT02364596?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2015-01. Estimated completion is 2015-02.
What conditions does trial NCT02364596 study?
This clinical trial studies the following conditions: Staphylococcal Infections.
What interventions are being tested in trial NCT02364596?
The interventions under investigation include: SA4Ag vaccine (BIOLOGICAL), Blood sample (PROCEDURE).
Who is sponsoring clinical trial NCT02364596?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02364596 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Staphylococcal Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
COMPLETED · Phase 1
-
Modeling Host-Pathogen Interaction Using Lymphoid Organoids
RECRUITING
-
Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.